Risk of Urogenital Infections in People With Type 2 Diabetes Initiating SGLT2is Versus GLP-1RAs in Routine Clinical Care: A Danish Cohort Study
Diabetes Care · 2025
DOI: 10.2337/dc24-2169 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diabetes Care, 2025. Verfasst von Christine Ljungberg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Urinary Tract Infections, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE Anticipated risks of urinary tract infections (UTI) and genital tract infections (GTI) associated with sodium–glucose cotransporter 2 inhibitors (SGLT2is) may prevent their use in clinical practice. We investigated whether initiation of SGLT2is, compared with glucagon-like peptide 1 receptor agonists (GLP-1RAs), was associated with an elevated risk of UTI and GTI in people with type 2 diabetes. RESEARCH DESIGN AND METHODS In this cohort study emulating a target trial, we included all adult metformin users initiating SGLT2is or GLP-1RAs in Denmark in 2016–2021 and used inverse-probability of treatment (IPT) weighting to balance potential confounders. We estimated IPT-weighted risk and risk ratios of community- or hospital-treated UTI and GTI, performing both intention-to-treat and on-treatment analyses. RESULTS This study included 52,414 SGLT2i initiators and 27,023 GLP-1RA initiators with a median follow-up of 2.9 to 3.9 years. The estimated risks of UTI within the first year were nearly identical: 10.0% for SGLT2is and 10.2% for GLP-1RAs in intention-to-treat analyses corresponding to a risk ratio of 0.98 (95% CI 0.94, 1.03). For GTI, the 1-year risks were elevated under SGLT2i therapy at 2.0% vs. 0.7% (risk ratio 2.95 [95% CI 2.52, 3.44]). During the 5-year follow-up, the relative UTI risk remained almost constant (0.96 [95% CI 0.94, 0.99]) whereas the GTI risk ratio with SGLT2is decreased to 1.64 (95% CI 1.49, 1.80). CONCLUSIONS In routine clinical care, SGLT2i initiation is not associated with increased risk of UTI compared with GLP-1RA initiation. However, early GTI risk is up to threefold larger in SGLT2i users.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
- Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark.
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
- Department of Medical Microbiology and Infection Control, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
ORCID-Profile: Christine Ljungberg, Frederik Pagh Bredahl Kristensen, Mette Nørgaard, Reimar Wernich Thomsen
Zitieren
APA
Ljungberg, C., Kristensen, F. P. B., Dalager-Pedersen, M., Vandenbroucke-Grauls, C., Sørensen, H. T., Nørgaard, M., & Thomsen, R. W. (2025). Risk of Urogenital Infections in People With Type 2 Diabetes Initiating SGLT2is Versus GLP-1RAs in Routine Clinical Care: A Danish Cohort Study. Diabetes Care. https://doi.org/10.2337/dc24-2169
Vancouver
Ljungberg C, Kristensen FPB, Dalager-Pedersen M, Vandenbroucke-Grauls C, Sørensen HT, Nørgaard M, et al. Risk of Urogenital Infections in People With Type 2 Diabetes Initiating SGLT2is Versus GLP-1RAs in Routine Clinical Care: A Danish Cohort Study. Diabetes Care. 2025. doi:10.2337/dc24-2169
BibTeX
@article{Ljungberg2025,
author = {Ljungberg, Christine and Kristensen, Frederik Pagh Bredahl and Dalager-Pedersen, Michael and Vandenbroucke-Grauls, Christina and Sørensen, Henrik Toft and Nørgaard, Mette and Thomsen, Reimar Wernich},
title = {Risk of Urogenital Infections in People With Type 2 Diabetes Initiating SGLT2is Versus GLP-1RAs in Routine Clinical Care: A Danish Cohort Study},
journal = {Diabetes Care},
year = {2025},
doi = {10.2337/dc24-2169}
}
EUVIMED